James R. Neal
CIK: 0001600865
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (18 total)
- Jul 26, 2026PCSA
Processa Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
62.2K shares- - Mar 31, 2026PCSA
Processa Pharmaceuticals, Inc.
Purchase(P)Direct789 shares at avg. $2.54$2K - Dec 16, 2025AKTX
Akari Therapeutics Plc
Purchase(P)DirectPre-Funded Warrants to purchase ADRs
2.5K shares at avg. $0.40- - Dec 16, 2025AKTX
Akari Therapeutics Plc
Purchase(P)DirectWarrants to purchase American Depositary Shares ("ADRs")
2.5K shares- - Dec 16, 2025AKTX
Akari Therapeutics Plc
Purchase(P)DirectWarrants to purchase ADRs
3.1K shares- - Dec 16, 2025AKTX
Akari Therapeutics Plc
Purchase(P)DirectPre-Funded Warrants to purchase ADRs
3.1K shares at avg. $0.40- - Oct 1, 2025PCSA
Processa Pharmaceuticals, Inc.
Award(A)DirectStock Options (Right to Buy)
300K shares- - Oct 1, 2025PCSA
Processa Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
100K shares- - Jul 24, 2025PCSA
Processa Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock
175.3K shares- - Mar 20, 2025AKTX
Akari Therapeutics Plc
Award(A)DirectStock Option (Right to Buy)
225K shares- - Mar 20, 2025AKTX
Akari Therapeutics Plc
Award(A)DirectStock Option (Right to Buy)
175K shares- - Mar 6, 2025AKTX
Akari Therapeutics Plc
Award(A)Direct4.5K shares at avg. $1.12$5K - Jan 9, 2025AKTX
Akari Therapeutics Plc
Award(A)Direct8M shares at avg. $0.00$5K - Dec 23, 2024AKTX
Akari Therapeutics Plc
Award(A)Direct2M shares at avg. $0.00$1K - Nov 14, 2024PKBO
Peak Bio, Inc.
Conversion(C)Direct37.9K shares- - Nov 14, 2024PKBO
Peak Bio, Inc.
Disposition(D)Direct37.9K shares- - Sep 3, 2024PCSA
Processa Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock
31.2K shares- - Sep 3, 2024PCSA
Processa Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock
31.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 26, 2026 |  PCSA Processa Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 62,221 | - | - | Direct |
| Mar 31, 2026 | PCSA Processa Pharmaceuticals, Inc. | Purchase(P) | 789 | $2.54 | $2,000 | Direct |
| Dec 16, 2025 |  AKTX Akari Therapeutics Plc | Purchase(P) Pre-Funded Warrants to purchase ADRs | 2,473 | $0.40 | - | Direct |
| Dec 16, 2025 | AKTX Akari Therapeutics Plc | Purchase(P) Warrants to purchase American Depositary Shares ("ADRs") | 2,473 | - | - | Direct |
| Dec 16, 2025 | AKTX Akari Therapeutics Plc | Purchase(P) Warrants to purchase ADRs | 3,093 | - | - | Direct |
| Dec 16, 2025 | AKTX Akari Therapeutics Plc | Purchase(P) Pre-Funded Warrants to purchase ADRs | 3,093 | $0.40 | - | Direct |
| Oct 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | Award(A) Stock Options (Right to Buy) | 300,000 | - | - | Direct |
| Oct 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 100,000 | - | - | Direct |
| Jul 24, 2025 | PCSA Processa Pharmaceuticals, Inc. | Award(A) Restricted Stock | 175,299 | - | - | Direct |
| Mar 20, 2025 | AKTX Akari Therapeutics Plc | Award(A) Stock Option (Right to Buy) | 225,000 | - | - | Direct |
| Mar 20, 2025 | AKTX Akari Therapeutics Plc | Award(A) Stock Option (Right to Buy) | 175,000 | - | - | Direct |
| Mar 6, 2025 | AKTX Akari Therapeutics Plc | Award(A) | 4,464 | $1.12 | $5,000 | Direct |
| Jan 9, 2025 | AKTX Akari Therapeutics Plc | Award(A) | 8,000,000 | $0.00 | $4,800 | Direct |
| Dec 23, 2024 | AKTX Akari Therapeutics Plc | Award(A) | 2,000,000 | $0.00 | $1,000 | Direct |
| Nov 14, 2024 |  PKBO Peak Bio, Inc. | Conversion(C) | 37,850 | - | $0 | Direct |
| Nov 14, 2024 | PKBO Peak Bio, Inc. | Disposition(D) | 37,850 | - | $0 | Direct |
| Sep 3, 2024 | PCSA Processa Pharmaceuticals, Inc. | Award(A) Restricted Stock | 31,206 | - | - | Direct |
| Sep 3, 2024 | PCSA Processa Pharmaceuticals, Inc. | Award(A) Restricted Stock | 31,206 | - | - | Direct |
1-18 of 18 transactions
About Neal James R
Neal James R (SEC CIK 0001600865) files insider reports with the SEC as Director of Processa Pharmaceuticals, Inc. (PCSA), Director of Akari Therapeutics Plc (AKTX) and Director of Peak Bio, Inc. (PKBO).
Signal8 holds 13 ownership filings by Neal James R (1 Form 3, 12 Form 4), filed between Sep 18, 2024 and Jul 28, 2026. Those filings report 18 transactions, from Sep 3, 2024 to Jul 26, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Neal James R's filings is in VERO BEACH, FL.
Recent filings by Neal James R
- Jul 26, 2026: Grant or award of PCSA derivative securities (Form 4, code A).
- Mar 31, 2026: Open-market purchase of PCSA shares (Form 4, code P).
- Dec 16, 2025: Open-market purchases of AKTX derivative securities (4 lines, Form 4, code P).
- Oct 1, 2025: Grants or awards of PCSA derivative securities (2 lines, Form 4, code A).
- Jul 24, 2025: Grant or award of PCSA derivative securities (Form 4, code A).
Other insiders filing for Processa Pharmaceuticals, Inc. (PCSA)
- Ng George K, Chief Executive Officer
- GUJRATHI SHEILA, Director
- Yorke Justin W, Director
- SKIBSTED RUSSELL, Chief Financial Officer
- Pannu Geraldine, Director
- Lin Patrick, Chief Business - Strategy Off